A powerful new tool for the separation of charged species
Postnova's new EAF4 system.
A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.
Traditional separation technology in these fields provides particle size or molar mass distributions as the final result. It is clear, however, that particle and molecular charge plays a primary role in many applications such as protein aggregation, polymer flocculation, particle agglomeration and in pharmaceutical formulations in general.
The new Postnova EAF2000 instrument using EAF4 technology opens a completely new way to a significantly better understanding of these phenomena by allowing the particle size or molar mass distributions to be further differentiated and transformed into charge distributions. This allows identifying charge heterogeneities, which may be present within the different size and molar mass fractions and will quickly help to aid research or establish more efficient product development processes.
The EAF2000 instrument works by combining the principle of electrical and flow field-flow fractionation (FFF) in one experiment. In flow FFF the molecules and particles are gently separated in an open channel which avoids any interaction with column packing material keeping aggregation and structures intact. The electrical field, either positive or negative, can now be applied during this separation to differentiate between differently charged species of the same size or molecular weight.
The new Postnova EAF2000 technology is also designed in such a way that it allows the determination of the electrophoretic mobility (or zeta-potential) of the separated analytes under investigation. This is a key new tool, particularly for protein research as existing techniques for zeta-potential are limited by concentration and are simple batch techniques giving just an average value for all components in the solution. The new EAF2000 can determine the zeta-potential of each individually separated component such as protein monomer and dimer (or higher aggregates) or antibody monomer and fragments/aggregates.
Early successes with the technology have been found in applications as diverse as the separation of a positively charged pharmaceutical protein formulation, determination of the difference in zeta-potential of protein monomer and dimer and the differentiation of charge on polymer latex particles.
There is the first chance to see this technology in action on 6 March at the 2nd Postnova FFF Seminar at the company's UK headquarters in Malvern (UK). Following the popularity of the first Postnova first seminar, an informative program of talks from eminent guest speakers, plus presentations from Postnova scientists has been assembled.
The free 2018 seminar has been designed to advance the attendees knowledge of applications and techniques in nanoscale characterisation. The seminar will be particularly useful to those interested in using FFF, Size Exclusion Chromatography (SEC/GPC) and Light Scattering/Viscometry (MALS/DLS), as well as those interested in how these techniques may be useful in their research.
With limited attendee spaces available please register now for this free Seminar by contacting Postnova Analytics at [email protected].
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...